Thera-SAbDab

INEBILIZUMAB

>   Structural Summary
TherapeuticInebilizumab
TargetCD19
Heavy ChainEVQLVESGGGLVQPGGSLRLSCAASGFTFSSSWMNWVRQAPGKGLEWVGRIYPGDGDTNYNVKFKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCARSGFITTVRDFDYWGQGTLVTVSS
Light ChainEIVLTQSPDFQSVTPKEKVTITCRASESVDTFGISFMNWFQQKPDQSPKLLIHEASNQGSGVPSRFSGSGSGTDFTLTINSLEAEDAATYYCQQSKEVPFTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Preregistration
Estimated Status (June '19)Active
Recorded Developmental TechnologyPOTELLIGENT Technology
INN Year Proposed2015
INN Year Recommended2016
Companies InvolvedCellective Therapeutics, MedImmune
Conditions Approvedna
Conditions ActiveNeuromyelitis optica, Chronic lymphocytic leukaemia, B-cell lymphoma, Follicular lymphoma, Multiple myeloma, Multiple sclerosis, Autoimmune disorders, Myasthenia gravis, Renal transplant rejection
Conditions Discontinued Systemic scleroderma, Diffuse large B cell lymphoma
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]